Low Blood Sugar After Gastric Bypass?

If you’re experiencing low blood sugar after gastric bypass surgery, you may qualify for a post-bariatric hypoglycemia clinical trial called LUCIDITY, now enrolling in your area. No insurance required. Space is limited.

See If You Qualify

About the LUCIDITY PBH Study

The LUCIDITY study is testing an investigational drug for adults with post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass surgery (RYGB). If you qualify and enroll, you may receive study-related care at no cost and reimbursement for expenses.

  • Must be 18 or older
  • Had RYGB surgery at least 12 months ago
  • Diagnosed with PBH
Lucidity Pbh

Why Participate?

If eligible, you may receive:

  • Free study-related care
  • Reimbursement for study-related costs
  • Access to the investigational drug in an extension phase
  • Ongoing health monitoring from a local research team

Understanding Post-Bariatric Hypoglycemia

Post-bariatric hypoglycemia (PBH) is a condition caused by insulin levels that are too high, leading to low blood sugar. It often develops a year or more after gastric bypass surgery. Symptoms may include sweating, anxiety, blurred vision, confusion, weakness, or even fainting. These symptoms typically occur 1 to 3 hours after eating a meal or snack.

PBH occurs because of an excessive release of a hormone called GLP-1 after meals. GLP-1 triggers insulin production in the pancreas. In people with PBH, GLP-1 levels become abnormally high, causing too much insulin to be released. This leads to blood sugar levels dropping too low after eating.

Currently, there are no approved treatments for PBH. Research is essential to finding safe and effective therapies for managing low blood sugar after gastric bypass surgery. The LUCIDITY study aims to see whether a new investigational drug can help reduce hypoglycemic episodes and improve quality of life.

What to Expect If You Join

Screening Period (up to 6 weeks)

 ✔ 1 in-person visit
 ✔ 1 remote or in-person follow-up

Double-Blind Treatment Period (16 weeks)

 ✔ You’ll receive either the study drug (avexitide) or placebo
 ✔ Ratio: 3 people get avexitide for every 2 who get placebo
 ✔ 5 in-person visits, 1 remote visit

Open-Label Extension (32 weeks)

 ✔ Everyone receives avexitide
 ✔ 6 in-person visits, 2 remote visits

Safety Follow-Up (4 weeks)

 ✔ 1 final in-person visit

Note: Study drug is given as a subcutaneous injection (under the skin).

Ready to Take the Next Step?

If you’re experiencing low blood sugar after gastric bypass surgery, you may qualify for the LUCIDITY post-bariatric hypoglycemia clinical trial, now enrolling in your area. This clinical trial is evaluating a potential treatment for post-bariatric hypoglycemia. No insurance required. Space is limited.

Answer a few questions

Tell us about your health, surgery, and symptoms.

Provide your contact info

We’ll use it to connect you to a local study site if you’re eligible.

Match with a study site

If you qualify, a team will follow up and guide you through next steps.

See If You Qualify